JP2021510833A5 - - Google Patents

Info

Publication number
JP2021510833A5
JP2021510833A5 JP2020558659A JP2020558659A JP2021510833A5 JP 2021510833 A5 JP2021510833 A5 JP 2021510833A5 JP 2020558659 A JP2020558659 A JP 2020558659A JP 2020558659 A JP2020558659 A JP 2020558659A JP 2021510833 A5 JP2021510833 A5 JP 2021510833A5
Authority
JP
Japan
Prior art keywords
cancer cells
treatment
k263ac
k263me
determining
Prior art date
Application number
JP2020558659A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019136532A5 (https=
JP7236164B2 (ja
JP2021510833A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2019/050025 external-priority patent/WO2019136532A1/en
Publication of JP2021510833A publication Critical patent/JP2021510833A/ja
Publication of JPWO2019136532A5 publication Critical patent/JPWO2019136532A5/ja
Publication of JP2021510833A5 publication Critical patent/JP2021510833A5/ja
Application granted granted Critical
Publication of JP7236164B2 publication Critical patent/JP7236164B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020558659A 2018-01-15 2019-01-15 治療法に対する応答を予測する薬剤及び方法 Active JP7236164B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2018900108 2018-01-15
AU2018900108A AU2018900108A0 (en) 2018-01-15 Proteinaceous molecules and uses therefor
AU2018900392A AU2018900392A0 (en) 2018-02-08 “agents and methods for predicting response to therapy”
AU2018900392 2018-02-08
PCT/AU2019/050025 WO2019136532A1 (en) 2018-01-15 2019-01-15 Agents and methods for predicting response to therapy

Publications (4)

Publication Number Publication Date
JP2021510833A JP2021510833A (ja) 2021-04-30
JPWO2019136532A5 JPWO2019136532A5 (https=) 2022-02-07
JP2021510833A5 true JP2021510833A5 (https=) 2022-02-07
JP7236164B2 JP7236164B2 (ja) 2023-03-09

Family

ID=67218185

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020558659A Active JP7236164B2 (ja) 2018-01-15 2019-01-15 治療法に対する応答を予測する薬剤及び方法

Country Status (8)

Country Link
US (1) US12174193B2 (https=)
EP (1) EP3740756A4 (https=)
JP (1) JP7236164B2 (https=)
CN (1) CN111936857B (https=)
AU (1) AU2019207535B2 (https=)
CA (1) CA3087779A1 (https=)
SG (1) SG11202006441SA (https=)
WO (1) WO2019136532A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4284949A4 (en) * 2021-01-28 2025-01-01 Ariel Scientific Innovations Ltd. SETDB1-MICROTUBULE INTERACTION AND ITS USE
CN113109565B (zh) * 2021-04-12 2024-02-02 中国人民解放军空军军医大学 一种评估患者对pd-1单抗产品敏感性的检测盒及其应用
CN117999357A (zh) 2021-06-14 2024-05-07 波士顿大学董事会 用于检测细胞应激的方法
CN115248313A (zh) * 2022-08-03 2022-10-28 中山市人民医院 肠癌外周血免疫细胞m5C标志物的应用
CN116381235A (zh) * 2022-11-28 2023-07-04 中国人民解放军海军军医大学第三附属医院 一种生物标志物sod3及其在肝癌治疗中的应用
WO2025234833A1 (en) * 2024-05-10 2025-11-13 Lunit Inc. Method and device for predicting cancer treatment response to immune checkpoint inhibitor
CN118522475B (zh) * 2024-07-22 2024-10-29 杭州茵菲多组学生物科技有限公司 基于组织原位质谱成像技术的非小细胞肺癌免疫检查点抑制剂疗法疗效评估方法及系统

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4018653A (en) 1971-10-29 1977-04-19 U.S. Packaging Corporation Instrument for the detection of Neisseria gonorrhoeae without culture
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4424279A (en) 1982-08-12 1984-01-03 Quidel Rapid plunger immunoassay method and apparatus
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
EP0491007B1 (en) 1989-09-08 1996-03-13 The Johns Hopkins University Structural alterations of the egf receptor gene in human gliomas
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
EP0659439B1 (en) 1993-12-24 2001-10-24 MERCK PATENT GmbH Immunoconjugates
US5679683A (en) 1994-01-25 1997-10-21 Warner-Lambert Company Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
US5675063A (en) 1995-02-28 1997-10-07 Loyola University Of Chicago Immortalized rabbit hybridoma fusion partner
MX9707453A (es) 1995-03-30 1997-12-31 Pfizer Derivados de quinazolina.
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
AU6267896A (en) 1995-06-07 1996-12-30 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth oftumors
MX9800215A (es) 1995-07-06 1998-03-31 Novartis Ag Pirrolopirimidas y procesos para su preparacion.
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
HU228446B1 (en) 1996-04-12 2013-03-28 Warner Lambert Co Kinazoline derivatives as irreversible inhibitors of protein-kinase, pharmaceutical compositions containing these compounds and use thereof
ID19609A (id) 1996-07-13 1998-07-23 Glaxo Group Ltd Senyawa-senyawa heterosiklik
ID18494A (id) 1996-10-02 1998-04-16 Novartis Ag Turunan pirazola leburan dan proses pembuatannya
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
ATE241986T1 (de) 1997-05-06 2003-06-15 Wyeth Corp Verwendung von chinazolin verbindungen zur behandlung von polyzystischer nierenkrankheit
ZA986729B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
CN1278176A (zh) 1997-11-06 2000-12-27 美国氰胺公司 喹唑啉衍生物作为用于治疗结肠息肉的酪氨酸激酶抑制剂的应用
WO2000031048A1 (en) 1998-11-19 2000-06-02 Warner-Lambert Company N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases
JP5064625B2 (ja) 1999-10-27 2012-10-31 バイオウルフ テクノロジーズ エルエルスィー パターンを同定するための方法及び機械
EP1386275A2 (en) 2000-07-18 2004-02-04 Correlogic Systems, Inc. A process for discriminating between biological states based on hidden patterns from biological data
EP1337845B1 (en) 2000-11-16 2012-01-04 Bio-Rad Laboratories, Inc. Method for analyzing mass spectra
US7113896B2 (en) 2001-05-11 2006-09-26 Zhen Zhang System and methods for processing biological expression data
US20020193950A1 (en) 2002-02-25 2002-12-19 Gavin Edward J. Method for analyzing mass spectra
US9689876B2 (en) * 2012-05-02 2017-06-27 New York University Methods related to cancer treatment
AR093984A1 (es) * 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
DK2971064T3 (da) 2013-03-12 2019-12-16 Ventana Med Syst Inc Nærhedsassay til in situ-påvisning af mål
EP2981821B2 (en) 2013-04-02 2021-11-03 Merck Sharp & Dohme Corp. Immunohistochemical assay for detecting expression of programmed death ligand 1 (pd-l1) in tumor tissue
AU2014364520B2 (en) * 2013-12-20 2020-01-02 The General Hospital Corporation Methods and assays relating to circulating tumor cells
US9856315B2 (en) 2014-10-15 2018-01-02 Cell Signaling Technology, Inc. Methylation and acetylation sites
GB201500319D0 (en) * 2015-01-09 2015-02-25 Agency Science Tech & Res Anti-PD-L1 antibodies
WO2016160792A1 (en) 2015-03-30 2016-10-06 Stcube & Co., Inc. Antibodies specific to glycosylated pd-l1 and methods of use thereof
CN111936509A (zh) * 2018-01-15 2020-11-13 艾比克斯治疗私人有限公司 蛋白质分子及其用途

Similar Documents

Publication Publication Date Title
JP2021510833A5 (https=)
Ren et al. TRAPPC4 regulates the intracellular trafficking of PD-L1 and antitumor immunity
Yan et al. Circular RNA circPICALM sponges miR-1265 to inhibit bladder cancer metastasis and influence FAK phosphorylation
Montemagno et al. Soluble forms of PD-L1 and PD-1 as prognostic and predictive markers of sunitinib efficacy in patients with metastatic clear cell renal cell carcinoma
Timofeeva et al. Influence of common genetic variation on lung cancer risk: meta-analysis of 14 900 cases and 29 485 controls
Wang et al. Decreased STAT4 indicates poor prognosis and enhanced cell proliferation in hepatocellular carcinoma
McAndrew et al. Effects of systemic inflammation on relapse in early breast cancer
Gantt et al. Gene expression profile is associated with chemoradiation resistance in rectal cancer
Li et al. High expression of CCR7 predicts lymph node metastasis and good prognosis in triple negative breast cancer
Huang et al. SOX2 promotes vasculogenic mimicry by accelerating glycolysis via the lncRNA AC005392. 2-GLUT1 axis in colorectal cancer
Zhang et al. Overexpression of dishevelled 2 is involved in tumor metastasis and is associated with poor prognosis in hepatocellular carcinoma
Fuentes-Rodriguez et al. Recent advances in molecular and genetic research on uveal melanoma
Jang et al. Proteomics of primary uveal melanoma: insights into metastasis and protein biomarkers
Zhang et al. The prognostic role of FZD6 in esophageal squamous cell carcinoma patients
Cui et al. Advances in multi-omics applications in HBV-associated hepatocellular carcinoma
Liu et al. The impact of high co-expression of Sp1 and HIF1α on prognosis of patients with hepatocellular cancer
Chen et al. SAMHD1, positively regulated by KLF4, suppresses the proliferation of gastric cancer cells through MAPK p38 signaling pathway
Abou-Fadel et al. Key members of the cmpn as biomarkers distinguish histological and immune subtypes of hepatic cancers
Li et al. TRIM31 triggers colorectal carcinogenesis and progression by maintaining YBX1 protein stability through ubiquitination modification
Zuo et al. Identification of hub genes and their novel diagnostic and prognostic significance in pancreatic adenocarcinoma
Zhang et al. The predictive value of monocarboxylate transporter 4 (MCT4) on lung adenocarcinoma patients treated with PD-1 inhibitors
Kikuta et al. Pfetin as a prognostic biomarker in gastrointestinal stromal tumor: novel monoclonal antibody and external validation study in multiple clinical facilities
Saleh et al. Low pathogenicity of anti‐desmoglein 3 immunoglobulin G autoantibodies contributes to the atypical clinical phenotypes in pemphigus
Cengiz et al. Can serum pin1 level be regarded as an indicative marker of nonalcoholic steatohepatitis and fibrotic stages?
JPWO2019136532A5 (https=)